[A21-85] Beclometasone/formoterol/glycopyrronium (asthma) - Addendum to Commission A21-18
Last updated 05.08.2021
Project no.:
A21-85
Commission:
Commission awarded on 22.06.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
Adult patients with asthma whose disease is not adequately controlled with a combination of medium- or high-dose ICS and LABA, and who experienced one or more asthma exacerbations in the previous year
Unchanged after addendum:
- Medium-dose ICS/LABA therapy: added benefit not proven.
- High-dose ICS/LABA therapy: added benefit not proven.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-18 | Beclometasone/formoterol/glycopyrronium (asthma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-08-05: A G-BA decision was published.